Complement C1 inhibitors - Pipeline Insight, 2024

Complement C1 inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Complement C1 Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement C1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Complement C1 Inhibitors Understanding

Complement C1 Inhibitors: Overview

Complement C1 is the defining component of the classical pathway. Within the C1qC1r2C1s2 complex, C1q functions as a molecular scaffold for C1r2C1s2 and C1q binding to its ligands activates these two serine proteases. The classic C1q ligands are antigen-bound antibodies and activated C1s cleaves C4 and C2 to initiate the complement cascade.

Function - Activation of the C1 complex initiates the classical complement pathway. This occurs when C1q binds to antigen-antibody complexes. The antibodies IgM or certain subclasses of IgG complexed with antigens are able to initiate the complement system: a single pentameric IgM can initiate the pathway, while several monomeric IgG molecules are needed. C1q can also be activated in other ways, for example by binding to pentraxins such as C-reactive protein or directly to the surface of pathogens.

Complement C1 Inhibitors - C1 inhibitor is a protease inhibitor that targets C1r and C1s enzymes of the classical pathway of complement, Hageman factor (factor XII) of the coagulation pathway, and the kallikrein system.

Complement C1 Inhibitors Emerging Drugs Chapters

This segment of the Complement C1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complement C1 Inhibitors Emerging Drugs

• Sutimlimab : Bioverativ

Sutimlimab is a monoclonal antibody that binds to C1s, a protein that is part of the classical complement pathway. In this way, the treatment may block all of the downstream steps in the C1s-mediated complement pathway, and potentially reduce RBC lysis. The treatment may, therefore, be able to prevent hemolytic anemia in CAD patients.The advantage of sutimlimab is that it blocks only one of the three arms of the complement pathway, and does not affect the other two pathways — the lectin and alternative pathways. Therefore, sutimlimab ensures that the complement pathway is not totally ineffective. The drug is currently in preregistration stage of development.

• ANX007 : Annexon

ANX007 is a clinical-stage investigational monoclonal antibody antigen-binding fragment (Fab) for the treatment of patients with complement-mediated neurodegenerative ophthalmic diseases. Formulated for IVT administration, ANX007 is designed to potently bind to C1q and inhibit activation of all downstream components of the classical complement cascade, including C3 and C5, but to not interfere with the normal function of C3 and C5 as part of other complement pathways. The drug is currently in phase II of development.

Further product details are provided in the report……..

Complement C1 Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Complement C1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Complement C1 Inhibitors

There are approx. 5+ key companies which are developing the Complement C1 Inhibitors. The companies which have their Complement C1 Inhibitors drug candidates in the most advanced stage, i.e. preregistration include, Bioverativ.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Complement C1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complement C1 Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement C1 Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement C1 Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Complement C1 Inhibitors R&D. The therapies under development are focused on novel approaches for Complement C1 Inhibitors.

Complement C1 Inhibitors Report Insights

• Complement C1 Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Complement C1 Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Complement C1 Inhibitors drugs?
• How many Complement C1 Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Complement C1 Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Complement C1 Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Complement C1 Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bioverativ
• Annexon
• Pharming Group NV
• CSL Behring
• Takeda
• Octapharma
• BioGenius
• True North Therapeutics

Key Products

• Sutimlimab
• ANX 007
• Conestat alfa
• Complement C1 inhibitor protein
• TAK-616
• OCTA-C1-INH
• Bicizar
• ANX 005
• BIVV 020